[go: up one dir, main page]

WO2004064789A2 - Composes antimuscariniques quaternaires destines au traitement de maladies vesicales - Google Patents

Composes antimuscariniques quaternaires destines au traitement de maladies vesicales Download PDF

Info

Publication number
WO2004064789A2
WO2004064789A2 PCT/US2004/000961 US2004000961W WO2004064789A2 WO 2004064789 A2 WO2004064789 A2 WO 2004064789A2 US 2004000961 W US2004000961 W US 2004000961W WO 2004064789 A2 WO2004064789 A2 WO 2004064789A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
physiologically acceptable
bladder
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/000961
Other languages
English (en)
Other versions
WO2004064789A3 (fr
Inventor
Ronald W. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Priority to CA002513188A priority Critical patent/CA2513188A1/fr
Priority to AU2004206846A priority patent/AU2004206846B2/en
Priority to US10/542,501 priority patent/US8481518B2/en
Priority to EP04702509A priority patent/EP1589968A4/fr
Publication of WO2004064789A2 publication Critical patent/WO2004064789A2/fr
Publication of WO2004064789A3 publication Critical patent/WO2004064789A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Definitions

  • This invention relates to methods of treating bladder disease, particularly urinary incontinence.
  • Urinary incontinence afflicts a large and diverse patient population.
  • AHCPR Health Care Policy and Research
  • NIDDK National Institute of Diabetes and Digestive and Kidney Diseases
  • the cost of incontinence was estimated as 1.8 billion Swedish crowns (1990 SEK, equivalent to $400 million 1995 U.S. dollars).
  • the elderly account for more than two thirds of the cost of incontinence in the U.S., and costs are expected to increase with the increasing proportion of elderly in society.
  • Muscarinic receptors are divisible into several subtypes (M ⁇ -M 5 for humans, m ⁇ -m 5 for animals and other cells) that are distinguishable based on binding of selective ligands. These muscarinic receptor subtypes exist in differing concentrations in different tissues (for a detailed description of anticholinergic agents and their use in treating various diseases, see: Foye, W.O., Principles Of Medicinal Chemistry, Lea and Febiger, Philadelphia, PA, pp.
  • the present invention targets muscarinic receptors by administration of novel antimuscarinic agents via a catheter to the bladder to attain prolonged maintenance of bladder control in otherwise incontinent patients while minimizing systemic side effects of the medication.
  • the drug oxybutinin chloride (4-diethylamino)2-butynyl-cc- cyclohexyl-a-hydroxybenzeneacetate HC1; trade name Ditropan®) is a standard antimuscarinic therapeutic agent for urinary incontinence.
  • the dose-related antimuscarinic side effects of oral oxybutynin include marked xerostomia, dry skin, blurred vision, nausea, and constipation. Severe mouth dryness occurred in 84% of subjects receiving 5 mg/kg four times/day (AHCPR, 1992). Side effects could be minimized by administration of this compound via clean intermittent self-catheterization directly into the bladder (intravesical administration). However, this required at least daily self-catheterization. Better restoration of bladder control required multiple catheter insertions each day.
  • a series of papers reported beneficial effects in different patient groups. The following are representative: Brendler et al.,
  • U.S. Patent No. 5,001,160 to McPherson et al. describes antimuscarinic agents for the treatment of neurogenic bladder disease.
  • the compounds disclosed were said to have longer durations of action than older anticholinergic agents such as methantheline and propantheline.
  • the majority of neurogenic bladder patients have spastic or hypertonic conditions.
  • Clinicians generally aim to convert this condition to hypotonia as a way to treat the primary problem of incontinence. Thus, when the condition has been "converted" to hypotonia, it can be managed in a straightforward way by intermittent catheterization.
  • Ri was a cycloalkyl of 3-6 carbons, most preferably cyclohexyl or cyclobutyl.
  • R 2 was lower alkyl, benzyl, para-substituted benzyl or cinnamyl.
  • the most preferred compound was 1-cyclobutyl-l-hydroxy-l- phenyl-3-(4-benzyl-l-piperazinyl)-2-propanone.
  • the compounds were prepared in conventional aqueous injection solutions.
  • Patent No. 5,001,160 also disclosed that extemporaneous injection solutions could be prepared from sterile pills, granules or tablets, and contained diluents, dispersing and surface active agents, binders, and lubricants, as well as the anticholinergic compound.
  • Tolterodine is a new antimuscarinic of comparable duration of action which is reported to cause a lower incidence of dry mouth ( ⁇ 9%). The following dose-related side effects were observed with tolterodine: diminished stimulated salivation after 3.2 mg, increased heart rate after 6.4 mg, and altered the nearpoint of vision after 12.8 mg. Six of 8 subjects reported micturition difficulties after a dose of 12.8 mg.
  • Terodiline has both anticholinergic and calcium antagonist properties, and effectively reduces abnormal bladder contractions caused by detrusor instability (Langtry et al., "Terodiline. A Review of its Pharmacological Properties, and Therapeutic Use in the Treatment of Urinary Incontinence," Drugs 40:748-761(1990)).
  • urge incontinence generally as a 25 mg dose twice daily
  • terodiline reduced micturition frequency and incontinence episodes.
  • Bladder volume at first urge and bladder capacity were increased. Children with diurnal enuresis respond similarly to a daily 25 mg dose.
  • Terodiline at 50 mg/day was said to be preferred by patients when compared with emepromum 600 mg/day or flavoxate 600 mg/day, and tended to reduce voluntary micturition frequency and episodes of incontinence more effectively than these other drugs.
  • Anticholinergic side effects were the most common ones reported.
  • Anhydroecgonine Derivatives as Anticholinergic Agents [0014] Anhydroecgonine methyl ester (AEME), the primary pyrolysis product of cocaine (Martin et al., "Pyrolysis and Volatilization of Cocaine,” J Anal Toxicol 13:158-162 (1989)), is structurally similar to arecoline and anatoxin A.
  • AEME Anhydroecgonine methyl ester
  • AEME turned out to be a potent non-competitive muscarinic antagonist in vitro (El-Fawal et al., "Airway Smooth Muscle Relaxant Effects of the Cocaine Pyrolysis Product, Methylecgonidine,” J Pharm Exp Ther 272:991-996 (1995)).
  • the antagonistic effects were insurmountable even with the addition of increasing amounts of acetylcholine (ACh).
  • ACh acetylcholine
  • the anticholinergic effects were irreversible, so that tissue exposed to AEME could not later attain its original magnitude of contraction.
  • Interstitial cystitis a syndrome occurring primarily in women, is characterized by urinary urgency and frequency, suprapubic pain, and petechial bladder mucosal hemorrhages upon distention under general anesthesia. Almost 50% of IC patients also suffer from allergies and irritable bowel syndrome, all of which are exacerbated by stress.
  • IgE immunoglobulin E
  • allergen antigen
  • Mast cells are found in juxtaposition to neurons and are also activated by direct nerve stimulation, as well as by ACh, neurotensin, and Substance P. Barbalias, GA, "Interstitial Cystitis: Bladder Training with Intravesical Oxybutynin," J. Urol. 163 : 1818-1822 (2000), demonstrated that intravesical administration of oxybutynin to women with interstitial cystitis resulted in an improvement in their signs and symptoms that was better than the improvement produced by simple expansion of the bladder with saline.
  • the parasympathetic nervous system plays a major role in regulating bronchomotor tone.
  • One drug used to treat respiratory disease, such as asthma is the quaternary anticholinergic agent isopropylatropine bromide, also called iprafropium bromide (Atrovent®) (Gross, H.J., "Iprafropium Bromide,” New Eng. J. Med. 319:486-494 (1988); "Anticholinergic Therapy: The State of the Art. Proceedings of a Symposium Held in Stratford-Upon Avon 8-9 September 1986," Higgenbottam et al, eds., Postgrad. Med. J.
  • iprafropium for respiratory therapy is the possibility of reaching elevated regional tissue (e.g., lung) concentrations with few systemic anticholinergic effects.
  • Another advantage of ipratropium compared to other anti-asthmatic drugs is its duration of action. Its pharmacologic effect becomes maximal in about an hour, and persists for several hours. A compound with these features may also be useful for long duration therapy of bladder disease.
  • antimuscarinic therapies are widely used for treatment of bladder diseases, but they are fraught with side effects, which not only limit their acceptance by patients, but also complicate medical management. What are needed are effective methods of treating bladder disease without the unpleasant side effects associated with the current standard therapeutics.
  • the present invention relates to a method for treating bladder disease in a subject.
  • This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of: (1) a compound having the formula
  • R and R are each independently C ⁇ -C 4 -alkyl, Ri is thienyl, phenyl, cyclopentyl or cyclohexyl, and X " is a physiologically acceptable anion; (2) a compound having the formula
  • Ri 2-thienyl or cyclopentyl
  • A is 3 ⁇ -(6,7-dehydro)-tropanyl methobromide, 3 ⁇ -tropanyl methobromide, or 3 ⁇ -(N-isopropyl)-nortropanyl methobromide; (5) a compound having the formula
  • R is an optionally halo- or hydroxyl-substituted C 1 - alkyl group
  • R 1 is a C ⁇ - 4 -alkyl group, or R and R 1 together form a C 4 - 6 -alkylene group
  • X " is a physiologically acceptable anion
  • Ri is H, OH, CH 3 , CH 2 OH, C1-4 alkyl or C ⁇ - 4 -alkoxy;
  • R is an optionally halo- or hydroxy-substituted C M -alkyl group
  • R 1 is a C M —alkyl group, or R and R 1 together form a C . 6 - alkylene group
  • X " is a physiologically acceptable anion and Ri is H, OH, CH 3 , CH 2 OH, CM -alkyl or C M -alkoxy; (7) a compound having the formula
  • Standard antimuscarinic medications for the treatment of detrusor instability or urge incontinence produce side effects that may be intolerable, particularly when taken in combination with other medications commonly used by the elderly.
  • the present invention is directed to overcoming these and other deficiencies in the art.
  • the present invention relates to a method for treating bladder disease in a subject.
  • This method involves administering to a subject a pharmaceutical composition having a therapeutic amount of a compound selected from the group consisting of: a compound having the formula
  • R and R 1 are each independently C ⁇ -C 4 -alkyl, Ri is thienyl, phenyl, cyclopentyl or cyclohexyl, and X " is a physiologically acceptable anion.
  • R may be, without limitation, CH 3 , C 2 H 5 , n-C 3 H 7 , or i-C 3 H ;
  • R 1 may be ,without limitation, CH 3j and X " is meant to include, without limitation, bromide (Br " ) and CH 3 SO 3 .
  • treatment of a bladder disease involves administering to a subject a compound having the formula CH 3
  • treatment of a bladder disease involves administering to a subject a compound having the formula
  • X- is a physiologically acceptable ion as described above.
  • treatment of a bladder disease involves administering to a subject a compound having the formula
  • Ri is 2-thienyl or cyclopentyl
  • A is 3 ⁇ -(6,7-dehydro)-tropanyl methobromide, 3 ⁇ -tro ⁇ anyl methobromide, or 3 ⁇ -(N-iso ⁇ ropyl)-nortropanyl methobromide.
  • treatment of a bladder disease involves administering to a subject a compound having the formula
  • R is an optionally halo- or hydroxyl-substituted C M alkyl group
  • R 1 is a . 4 alkyl group, or R and R 1 together form a C 4 - 6 -alkylene group
  • X " is a physiologically acceptable ion as described herein above
  • Ri is H, OH, CH 2 OH, C M alkyl or C M alkoxy.
  • treatment of a bladder disease involves administering to a subject a compound having the formula
  • R is an optionally halo- or hydroxyl-substituted C M alkyl group
  • R 1 is a Ci- 4 alkyl group, or R and R 1 together form a C 4 - 6 -alkylene group
  • X " is a physiologically acceptable ion as described herein above
  • Ri is H, OH, CH 2 OH, C M alkyl or C M alkoxy.
  • treatment of a bladder disease involves administering to a subject a compound having the formula:
  • treatment of a bladder disease involves administering to a subject a compound having the formula
  • treatment of a bladder disease involves administering to a subject a compound having the formula
  • An exemplary compound for use in the method of the present invention is tiofropium bromide (6 ⁇ ,7 ⁇ ,Epoxy-3 ⁇ -[2-hydroxy-2,2-di(2- thienyl)acetoxy]-8,8-dimethyl-l ⁇ H,5 ⁇ H-tropanium bromide) (Norman et al., "Tiofropium Bromide, Treatment of COPD Bronchodilator Muscarinic Antagonist," Drugs of the Future 25(7):693-699 (2000), which is hereby incorporated by reference in its entirety).
  • This new generation compound has been shown to have unique pharma, exhibiting a specific highly potent antagonism at all subtypes of human muscarinic receptors in the 10-11 M range in vitro (KD-value from kinetic measurements at M 3 : 14 pM) (Disse et al., "Ba 679 BR, A Novel Long- Acting Anticholinergic Bronchodilator," Life Sci
  • Tiofropium similar to iprafropium, is in the classical view not subtype-selective (based on similar KD values at muscarinic receptor subtypes). However, tiofropium dissociation from M 2 (3.6 hours) is faster than from M 3 -receptors (35 hours) which, in functional experiments, is manifest as a "kinetic type" of receptor subtype selectivity of M 3 (and Mi) over M 2 receptors (Takahashi et al., "Effect of Ba 679 BR, A Novel Long- Acting Anticholinergic Agent, On Cholinergic Neurotransmission in Guinea Pigs and Human Airways," Am JResp Crit Care Med 150:1640-1645 (1994), which is hereby incorporated by reference in its entirety).
  • a wide variety of patient populations may benefit from these medications, especially those with urge and frequency incontinence, detrusor instability, and detrusor-external sphincter dyssynergia.
  • a non-exclusive list of exemplary conditions to which the present invention is suitable include: urge incontinence, cystitis (including interstitial cystitis), bladder dysfunction of multiple sclerosis, benign prostatic hyperplasia, myelomeningocele (spina bifida), spinal cord injury, patients with dementias for whom antimuscarinic medications are contraindicated, parkinsonism, and patients who cannot tolerate systemic effects of antimuscarinic medications because of concurrent medication with other agents or because of blurred vision, dry mouth, constipation, cognitive impairment or other sequelae of antimuscarinic medications.
  • the present invention relates to a method for treating bladder disease comprising administering an antimuscarinic agent or a derivative or analogue thereof as described above in a pharmaceutically acceptable carrier or excipient for intravesical instillation.
  • a pharmaceutically acceptable carrier or excipient for intravesical instillation are materials which enhance viscosity or promote the entry of the active agent into the bladder wall, including carboxymethyl celluloses, glycosaminoglycans (GAGs), pentosan polysulfate, heparin, or heparin-like compounds, hi one aspect of the present invention, the treatment includes the physical or pharmacological creation of a depot/slow release compartment for the composition.
  • the agent can be achieved, for example, by delivery of the agent using liposomes or other known delivery agents having the noted action on release.
  • Another approach involves the use of protamine (or a protamine-like compound) to alter the surface of the bladder, thereby fostering access or to enhance access.
  • the subject is first treated with protamine or a protamine-like agent, followed by administration of the active antimuscarinic agent in combination with a glycosoaminoglycans.
  • the endogenous intravesical GAG compartment is exchanged with, or replaced by, an exogenously applied mixture that incorporates the antimuscarinic composition of this invention.
  • Suitable additions would also include those which would provide the formulation with a longer mechanical presence in the bladder, allowing the compound of the present invention to diffuse from the bladder tissue, find a site on the bladder wall, or enhance the ability of the compound to infiltrate the tissue, and/or provide a slow release of existing pools of drug from the tissue.
  • the preferred antimusc-irinic agent has (1) receptor-selective activity, and (2) the activity is of long duration in the target organ following local administration to an internal surface of that organ.
  • An example from the art of treating asthma is the local application of isopropylatropine to the inner surface of the lung. If the agent is not given in excess dosage, long duration side effects should not occur. Quaternization does not eliminate peripheral activity; one of the primary purposes of this chemical change is to prevent passage of the agent across the blood-brain barrier.
  • An agent may achieve long duration of action by having high affinity for, or slow off-rates from, the receptor responsible for its clinically useful effect.
  • the agent may be retained in the body for a prolonged period of time, or differentially partition into or be retained within a compartment of the body in which the agent exerts its desirable effects.
  • the urothelium is lined with glycoprotein and glycosaminoglycan structures that present a negative charge to the lumen of the bladder; one consequence is the ordering of water molecules into layers at the bladder surface, a phenomenon that may play a role in urothelial barrier function. Since intravesically administered quaternary agents have a positive charge, they may be electrostatically attracted to this surface where they may bind.
  • antimuscarinic is interchangeable with “anticholinergic.”
  • Acetylcholine is a flexible compound that changes in length and therefore the same compound (in different conformations) fits nicotinic and muscarinic acetylcholine receptors.
  • atropine-like drugs such as iprafropium
  • both anticholinergic and antimuscarinic are correct, the latter being preferred by the pharmacologic purist (Witek, T. J. Jr., "Anticholinergic Bronchodilators,” Respiratory Clinica of North America 5:521-536 (1999), which is hereby incorporated by reference in its entirety).
  • a composition used to treat bladder disease is preferably substantially irreversible, meaning that it has a prolonged duration of action compared to a conventional muscarinic antagonist. This may be a result of covalent bonding to a receptor or another site of the cell, or because of a slow "off rate". This term is not intended to imply that one cannot measure an "off rate” (as in the case of hydrolysis of a xenobiotic where the receptor is left in a free state).
  • a compound preferably has a duration of pharmacologic effect of at least 12 hours, more preferably at least 24 hours, more preferably at least 7 days, even more preferably at least about 3 weeks.
  • the desired pharmacologic effect is that of increased residual bladder volume and/or reduced peak intravesical pressure, leading to the prevention of unwanted episodes of micturition.
  • termination of an agent's action may result from a number of processes including tolerance of the subject, dissociation from the receptor, receptor upregulation, breakdown of the agent in situ, and the associated return of the receptor to the functional population.
  • the criteria for the inclusion of a compound in the present invention are its ability to mimic the actions of an anticholinergic drug, such as oxybutynin, but with a longer duration of action.
  • the compounds of this invention must have an action that results in one or, preferably, a combination, of the following outcomes: (1) decreased peak intravesical pressure during voiding; (2) increased bladder capacity; (3) increased interval between voids. Furthermore, the compound should have few side effects and be well-tolerated by patients. Side effects are minimized in several ways, compared to drags in the prior art. First, intravesical administration, the preferred route, itself results in fewer systemic effects than systemic administration of the drug.
  • alkyl or “alkylene” is intended to include both branched and straight-chain aliphatic hydrocarbon groups having a specified number of carbon atoms.
  • alky groups include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl.
  • Alkoxy or "alkyloxy” as used herein represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s- pentoxy.
  • alkylthio or “thioalkoxy” as used herein represents an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge.
  • pharmaceutically acceptable ions refers to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like.
  • the pharmaceutically acceptable salts include the conventional non- toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include, without limitation, those derived from inorganic acids including hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric, and the like; and the salts prepared from organic acids including, without limitation, acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmist, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two.
  • nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., p. 1418, Mack Publishing Company, Easton, PA (1985), which is hereby incorporated by reference in its entirety.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une méthode destinée au traitement d'une maladie vésicale, y compris l'incontinence urinaire, consistant à administrer par voie intravésicale des composés antimuscariniques quaternaires ayant une durée d'action plus longue et entraînant moins d'effets secondaires que les traitements classiques.
PCT/US2004/000961 2003-01-16 2004-01-15 Composes antimuscariniques quaternaires destines au traitement de maladies vesicales Ceased WO2004064789A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002513188A CA2513188A1 (fr) 2003-01-16 2004-01-15 Composes antimuscariniques quaternaires destines au traitement de maladies vesicales
AU2004206846A AU2004206846B2 (en) 2003-01-16 2004-01-15 Quaternary antimuscarinic compounds for the treatment of bladder diseases
US10/542,501 US8481518B2 (en) 2003-01-16 2004-01-15 Quaternary antimuscarinic compounds for the treatment of bladder diseases
EP04702509A EP1589968A4 (fr) 2003-01-16 2004-01-15 Composes antimuscariniques quaternaires destines au traitement de maladies vesicales

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44139103P 2003-01-16 2003-01-16
US60/441,391 2003-01-16

Publications (2)

Publication Number Publication Date
WO2004064789A2 true WO2004064789A2 (fr) 2004-08-05
WO2004064789A3 WO2004064789A3 (fr) 2005-03-24

Family

ID=32771923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000961 Ceased WO2004064789A2 (fr) 2003-01-16 2004-01-15 Composes antimuscariniques quaternaires destines au traitement de maladies vesicales

Country Status (5)

Country Link
US (1) US8481518B2 (fr)
EP (1) EP1589968A4 (fr)
AU (1) AU2004206846B2 (fr)
CA (1) CA2513188A1 (fr)
WO (1) WO2004064789A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632229A1 (fr) * 2004-08-11 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co. KG Médicaments pour le traitement des maladies des voies urinaires contenant des anticholinergiques
WO2006134021A3 (fr) * 2005-06-15 2007-04-19 Boehringer Ingelheim Int Procede de preparation de nouveaux sels de tiotropium, nouveaux sels de tiotropium en tant que tels et compositions pharmaceutiques associees
WO2007086554A1 (fr) * 2006-01-30 2007-08-02 Ono Pharmaceutical Co., Ltd. Compose de tropane et composition pharmaceutique le contenant en tant qu’ingredient actif
WO2008104955A1 (fr) * 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Dérivés d'azoniatricyclo [3.3.1.0] nonane comme antagonistes des récepteurs muscariniques
WO2021198777A1 (fr) 2020-03-30 2021-10-07 Trizell Ltd. Compositions et méthodes pour traiter le cancer

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201502104YA (en) 2012-09-18 2015-05-28 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium
EP3829582A4 (fr) 2018-08-01 2022-04-27 TARIS Biomedical LLC Procédés de traitement de vessie hyperactive à l'aide de trospium

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2648667A (en) 1951-04-18 1953-08-11 Hoffmann La Roche Esters of 1-azabicycloalkanols
US4467095A (en) 1969-02-10 1984-08-21 Fmc Corporation Anticholinergic compounds
US5001160A (en) 1988-04-28 1991-03-19 Marion Laboratories, Inc. 1-aryl-1-hydroxy-1-substituted-3-(4-substituted-1-piperazinyl)-2-propanones and their use in treatment of neurogenic bladder disorders
US5236956A (en) * 1988-11-04 1993-08-17 Kabi Pharmacia Aktiebolag Compounds for the treatment of urinary incontinence
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE4108393A1 (de) 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
US5770738A (en) * 1992-03-05 1998-06-23 Boehringer Ingelheim Kg Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions
US5552407A (en) 1993-06-11 1996-09-03 New York University Medical Center Anhydroecgonine compounds and their use as anticholinergic agents
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US5779661A (en) * 1995-12-11 1998-07-14 Physion, S.R.L. Method of treating dysfunctional bladder syndromes by electromotive drug administration
US6171298B1 (en) * 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
EP0909170A4 (fr) * 1996-07-01 2000-02-09 Sepracor Inc Procedes et compositions de traitement de l'incontinence urinaire a l'aide de (s)-tridihexethyle enrichi en enantiomeres
US6204285B1 (en) * 1996-07-01 2001-03-20 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (R,R)-glycopyrrolate
EP0957916A4 (fr) 1996-07-01 2000-02-23 Sepracor Inc Procedes et compositions pour traiter l'incontinence urinaire avec du (r)-clidinium enrichi par enantiomorphisme
US6063808A (en) * 1996-07-01 2000-05-16 Sepracor Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (S,S)-glycopyrrolate
US6124354A (en) * 1996-07-29 2000-09-26 Pharmacia & Upjohn Ab Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6183461B1 (en) * 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
DE10203749A1 (de) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
US6974820B2 (en) * 2002-11-06 2005-12-13 Bridge Pharma, Inc. Methods for treating urinary incontinence and other disorders using trospium
EP1652532A1 (fr) * 2003-07-16 2006-05-03 Kyowa Hakko Kogyo Co., Ltd. Composition medicinale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1589968A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632229A1 (fr) * 2004-08-11 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co. KG Médicaments pour le traitement des maladies des voies urinaires contenant des anticholinergiques
WO2006134021A3 (fr) * 2005-06-15 2007-04-19 Boehringer Ingelheim Int Procede de preparation de nouveaux sels de tiotropium, nouveaux sels de tiotropium en tant que tels et compositions pharmaceutiques associees
RU2418796C2 (ru) * 2005-06-15 2011-05-20 Берингер Ингельхайм Интернациональ Гмбх Способ получения новых солей тиотропия
WO2007086554A1 (fr) * 2006-01-30 2007-08-02 Ono Pharmaceutical Co., Ltd. Compose de tropane et composition pharmaceutique le contenant en tant qu’ingredient actif
WO2008104955A1 (fr) * 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Dérivés d'azoniatricyclo [3.3.1.0] nonane comme antagonistes des récepteurs muscariniques
WO2021198777A1 (fr) 2020-03-30 2021-10-07 Trizell Ltd. Compositions et méthodes pour traiter le cancer

Also Published As

Publication number Publication date
US8481518B2 (en) 2013-07-09
CA2513188A1 (fr) 2004-08-05
AU2004206846A1 (en) 2004-08-05
WO2004064789A3 (fr) 2005-03-24
US20060154951A1 (en) 2006-07-13
EP1589968A4 (fr) 2009-05-06
EP1589968A2 (fr) 2005-11-02
AU2004206846B2 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
JP4801042B2 (ja) パーキンソンプラス症候群の治療及び予防のためのロチゴチンの使用
US6482837B1 (en) Antimuscarinic compounds and methods for treatment of bladder diseases
KR20130065650A (ko) 수면의 질 개선 방법
JP5020069B2 (ja) 下肢静止不能症候群および嗜癖障害の処置に有用なα−アミノアミド誘導体
CN1527708A (zh) 间质性膀胱炎治疗用医药组合物
JP4867123B2 (ja) 神経因性疼痛治療剤および神経因性疼痛のモデル動物
AU2004206846B2 (en) Quaternary antimuscarinic compounds for the treatment of bladder diseases
MXPA04010934A (es) Composiciones y metodos para combatir disfunciones del tracto urinario inferior con agonistas del receptor delta-opioide.
RU2493851C2 (ru) Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинестеразы, содержащая ее фармацевтическая композиция и ее применение в лечении когнитивных расстройств
CN101272776B (zh) 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途
AU2016377872A1 (en) Suplatast tosilate for treating cough associated with interstitial lung disease
AU2020397173A1 (en) Use of a KV7 potassium channel opener for treating pain
US20070281924A1 (en) MIF inhibitors for treating neuropathic pain and associated syndromes
US20110021542A1 (en) Use of a Combination of Udenafil and Alfuzosin or Oxybutynin for the Treatment of Overactive Bladder
JPH0269417A (ja) 精神分裂病治療用組成物
JP2004524270A (ja) 長時間作用する麻酔薬および鎮痛薬としての、三環式抗うつ薬およびのそれらのアナログ
US8258185B2 (en) Use of neboglamine in the treatment of toxicodependency
US8901177B2 (en) Method of treating bladder disorders
CN103877096B (zh) 盐酸氯卡色林在制备抑制阿片类物质成瘾和戒断反应的药物中的应用
CN110507652A (zh) 药物硝苯地平的新用途
EP2787991A1 (fr) Composition pharmaceutique comprenant un antagoniste de trpa1 et un agent anticholinergique
Hoshi et al. Muscarinic Antagonists and Their Clinical Uses
US20070191365A1 (en) 3,4,6-Substituted pyridazines for treating neuropathic pain and associated syndromes
WO2007145874A1 (fr) Traitement anti-nicotine consistant à utiliser trois agents anticholinergiques
CN120114433A (zh) 一种天然苯酸类化合物在制备治疗胃肠道疾病的药物中的应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2513188

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004206846

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004702509

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004206846

Country of ref document: AU

Date of ref document: 20040115

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004206846

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004702509

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006154951

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10542501

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10542501

Country of ref document: US